Therapeutic Area Director
8+ years of experience
Hardik’s interest in oncology stems from the cutting-edge drug development caused by the critical need for more effective treatments. He aims to provide clients with the tools that will assist them in making greater contributions to the advancement of oncology treatments.
Since joining Datamonitor Healthcare in 2013, Hardik has contributed content and insights on diseases within the oncology, respiratory, and immunology and inflammation therapeutic areas.
He holds a BSc in Biomedical Engineering and a Masters in Engineering and Management, both from Case Western Reserve University.
ターゲット市場の実像をつかむ, Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharmaprem...
By Hardik Patel 16 Jun 2022
Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019.
By Hardik Patel 18 Oct 2015
Immunotherapies are one of the fastest growing treatment algorithms in pharma at the moment, and non-small cell lung cancer (NSCLC) is just one area of oncology that is going to make the transition into being dominated by this type of therapy.
By Hardik Patel 05 Dec 2014
Download your free infographic using the adjacent form. Get to grips with early-phase opportunities in our non-small cell lung cancer (NSCLC) pipeline with our latest infographic.